827results about How to "Low water solubility" patented technology

A dermatological composition comprising a salt of a cation and an anion. The cation is derived from a monomeric or polymeric molecule that will generate an amidine moieity, a guanidine moieity or a biguanide moieity. The anion is derived from a monomeric or polymeric molecule that will generate a carboxylic acid moieity. The composition may be prepared by a metathesis or acid-base reaction.

Disclosed is a method for delivery of at least one therapeutic agent from an angioplasty balloon for treating vascular disease at a bifurcated vessel. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to a method of loading multiple beneficial agents onto the balloon surfaces

Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid-compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

The invention relates to polymers with antimicrobial properties, consisting of: a) 99-40 wt % non functional vinylically polymerizable monomers and b) 1-60 wt % functional vinylically polymerizable monomers of general formula (I) wherein V=vinyl, (meth)acroyl, allyl or styryl, A=a possibly available linking unit, which can be alkyl, aryl, arylalkyl or hydroxy alkyl, which can also be interrupted by hetero atoms, e.g. by hetero atoms in urethane, carbonate, ester, amide or ether groups, wherein y=0 or is 1, Hsp=a hydrophilic spacer of general formula (i) -(O-CH2-CH2)r- and / or (ii) -(O-CH2-CH(CH3))s with r=0-40, s=0-40 and r+s=2-40, also m=1.2 or 3 and R1=CH3, ethyl or benzyl, R2=an alkyl radical with 8-20 C-atoms, wherein t=1, 2 or 3 and X-=Cl-, Br-, I- or alkyl sulphate.

Disclosed is a method for delivery of at least one therapeutic agent from an angioplasty balloon for treating vascular disease at a bifurcated vessel. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to a method of loading multiple beneficial agents onto the balloon surfaces

Disclosed is an interventional device for delivery of therapeutic agents from an angioplasty balloon and from a prosthesis such as an intraluminal stent. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to an interventional device having a prosthesis surface that is loaded with a first beneficial agent, and a balloon surface loaded with a second beneficial agent. The invention also relates to a method of loading multiple beneficial agents onto the prosthesis surfaces and the balloon surfaces, and to a method of manufacturing an interventional device for the delivery of a first beneficial agent and a second beneficial agent from separate surfaces.

The present invention is directed to the oral osmotic delivery of therapeutic compounds that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation limitations in the core of the osmotic system. The present invention is suitable for the osmotic delivery of glipizide and other hydrophobic drugs, but runs the spectrum to other therapeutic agents with higher aqueous solubilities, yet having a solubility limitation in an osmotic dosage unit due to high drug load.

The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.

A herbicidal composition comprises in aqueous solution a mixture of salts of glyphosate at a total glyphosate a.e. concentration not less than about 360 g / l, wherein (a) said glyphosate is in anionic form accompanied by low molecular weight non-amphiphilic cations in a total molar amount of about 100% to about 120% of the molar amount of said glyphosate; (b) said cations comprise potassium and propylammonium (e.g., isopropylammonium) cations in a mole ratio of about 70:30 to about 90:10; and (c) said potassium and propylammonium cations together constitute about 90 to 100 molar percent of all of said low molecular weight non-amphiphilic cations in the composition.

A microsoftgel coated ammonium polyphosphate is prepared through suspending the ammonium polyphosphate particles in disperser, adding melamine, formaldehyde and hardening agent at 60-150 deg.C, stirring while reaction, adding formaldehyde capture, stirring while reacting at 30-60 deg.C for 10-30 min, filtering and drying. It can be used as flame-retarding agent.

A free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1 to 30 percent by weight of the drug, 5 to 60 percent by weight of a surfactant, 10 to 40 percent by weight of water; 1 to 20 percent by weight of unsaturated fatty acid ester, 0 to 50 percent by weight water miscible pharmaceutically acceptable polyol and 1 to 10 percent by weight of phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixture. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form.

The, present invention provides useful adhesive compositions having similar adhesive properties to conventional UF and PPF resins. The compositions generally include a protein portion and modifying ingredient portion selected from the group consisting of carboxyl-containing compounds, aldehyde-containing compounds, epoxy group-containing compounds, and mixtures thereof. The composition is preferably prepared at a pH level at or near the isoelectric point of the protein. In other preferred forms, the adhesive composition includes a protein portion and a carboxyl-containing group portion.

Chewing gums and methods of making same that have prolonged and enhanced sensory benefits are provided. The chewing gums of the present invention include a hydrophobic sweetener, a sensorally active component or trigeminal stimulant, such as a flavor, in addition to other typical chewing gum ingredients. The hydrophobic sweeteners are composed of sweet organic compounds that have a low water solubility.

A cleaning solution for cleaning a substrate for semiconductor devices and a cleaning method using the said cleaning solution, which comprises at least the following components (A), (B) and (C): (A) an ethyleneoxide-type surfactant containing a hydrocarbon group which may have a substituent group except for phenyl, and a polyoxyethylene group in which a ratio (m / n) of a number (m) of carbon atoms contained in the hydrocarbon group to a number (n) of oxyethylene groups contained in the polyoxyethylene group is in the range of 1 to 1.5, the number (m) of carbon atoms is not less than 9, and the number (n) of oxyethylene groups is not less than 7; (B) water; and (C) alkali or an organic acid. The cleaning solution highly clean the surface of the substrate without occurrence of corrosion by removing fine particles and organic contaminants which are adhered onto the surface of the substrate.

The invention relates to a method for preparing core-shell silicon dioxide-coated ammonium polyphosphate (APP), which is characterized by comprising the following steps successively: (1) adding ammonium polyphosphate into ethanol water solution, stirring and dispersing well; (2) adding silicate ester ethanol solution into the solution obtained in the step (1) while the mass ratio of silicate ester to ammonium polyphosphate is 0.05-10:1, adjusting the pH value of the solution to 9-12 by adding alkaline solution, and then performing complete reaction at room temperature; and (3) adding couplingagent into the grout obtained in the step (2) to carry out surface treatment, and then filtrating, washing and drying to obtain the silicon dioxide-coated ammonium polyphosphate. On one hand, the ammonium polyphosphate flame retardant utilizes the synergistic flame retardance of silicon and phosphorus elements to increase retardant effectiveness and reduce dosage, thereby bringing down the negative effects of APP; on the other hand, the ammonium polyphosphate flame retardant utilizes the advantages of silicon dioxide, such as excellent hydrophobicity, heat resistance, high strength and the like, to further solve the problems of APP such as infiltration and migration, influence on product strength, insufficient heat resistance and the like.

Disclosed is a method for delivery of at least one therapeutic agent from an angioplasty balloon for treating vascular disease at a bifurcated vessel. The invention also relates to the method of loading the beneficial agents onto the balloon and the device, as well as the method of delivery of the agents from separate surfaces. The invention also relates to a method of loading multiple beneficial agents onto the balloon surfaces

Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.

The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.

The invention relates to a method for efficiently extracting lithium from salt lake brine. The method comprises the following steps: (1) forming an extraction organic phase by an extraction agent, a co-extraction agent and a diluent, and then mixing the extraction organic phase with salt lake brine according to the volume ratio of (3-4):2 for three-stage extraction with single extraction time being 2-10 minutes to obtain an organic phase; and (2) mixing the organic phase obtained in step (1) with a reverse extraction acid solution (0-1 mol / L) for three-stage reverse extraction with single reverse extraction time being 2-10 minutes, and collecting an aqueous phase which is an aqueous solution containing lithium ions. The co-extraction agent of an extraction system of the method is hydrophobic ionic liquid, compared with conventional synergist ferric trichloride, the interference caused by iron ions is avoided, the reverse extraction acidity is greatly reduced, more importantly the lithium-magnesium separation factor is significantly improved, and the elution step of magnesium ions is reduced; in addition, the method provided by the invention is easy in process, easy to control, high in operation reliability, and good in recyclability of the organic phase, and greatly reduces the production cost for extracting the lithium from the salt lake brine.

The invention relates to an ammonium polyphosphate and montmorillonite nano compound and a preparation method thereof, which belong to the phosphorous compound preparation, composition, modification and crystalline control field. The method for preparing the nano compound comprises the following steps: montmorillonite is added during the preliminary stage of the process of general preparation of ammonium polyphosphate; ammonia is passed through when the temperature is raised to between 150 and 300 DEG C; heat preservation is performed when the temperature is raised to between 300 and 350 DEG C; and then the ammonium polyphosphate and montmorillonite nano compound are obtained after continuous ammoniation for 30 to 200 minutes. The preparation method controls the purity of an I-type polyphosphoric acid in the product through addition of a specific amount of the montmorillonite; the ammonium polyphosphate completely off a silicate slice of the montmorillonite; and nano-dispersion is formed in the ammonium polyphosphate, and then the ammonium polyphosphate and montmorillonite nano compound is obtained. The nano compound reduces the water solubility of the ammonium polyphosphate, has the function of improving the flame-retardant effect in inflaming retarding of polymer materials, and has the advantages of simple preparation technology and raw materials and low cost.

The present invention relates to novel amino acid salts of fumaric acid monoalkylesters. The salts are suitable for use as active substances in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders.

The present invention relates to compositions and methods for enhancing the bioavailability of beneficial agents with low water solubility.

N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy}propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically acceptable digestible oil, a surfactant, or a cosolvent, or a mixture of any two or more thereof. In one embodiment of the present invention are self-emulsifying or self-microemulsifying composition comprising 1) Compound I; 2) a surfactant having an HLB of 1 to 8; and 3) a surfactant having an HLB of over 8 to 20; and optionally, 4) a digestible oil and / or cosolvent and / or antioxidant or preservative.

A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and / or prophylactically active substance which has a relatively low aqueous solubility and / or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and / or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.

The invention discloses a carboxylic acid compound as well as a preparation method and application thereof. When the carboxylic acid compound is applied to extraction separation of metal ions, the separation coefficient is high, the reverse extraction acidity is low, the load rate is high, and the reverse extraction rate is high. The carboxylic acid compound serving as an extraction agent is highin stability and low in water solubility, so that the extraction process is stable, the environmental pollution can be reduced, and the cost is reduced. The carboxylic acid compound disclosed by the invention is low in cost, has a great application prospect and can be used for various systems such as ternary battery recovery and battery-grade nickel sulfate preparation.

The invention provides a hydrofining catalyst and a preparation method thereof. The catalyst comprises an aluminum oxide carrier which is modified by an assistant and VIII group and VIB group metal oxides which are loaded on the carrier, wherein, the assistant is at least one of boron, phosphorus, silicon and titanium compounds. The catalyst is prepared by an immersion method which is characterized in that an organic stabilizer is added into immersion fluid; the number of metal active centers of the catalyst is increased with the addition of the organic stabilizer; the physicochemical properties of the catalyst is improved by the way the aluminium oxide is modified by the assistant; therefore, the hydrofining catalyst prepared by the method in the invention has high desulfuration and denitrification activity, and is applicable to the hydrotreating process of various distillate oil, in particular to poor quality diesel oil.

A pharmaceutical composition comprises uncoated particles of a single thermodynamic equilibrium reversed cubic phase material containing an active agent disposed within. The uncoated particles have an anionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent.